CARGO discontinues the FIRCE-1 study, reducing workforce by 50% while advancing CRG-023 into Phase 1 trials.
Quiver AI Summary
CARGO Therapeutics, Inc. announced the discontinuation of its FIRCE-1 Phase 2 clinical study of firicabtagene autoleucel (firi-cel) for large B-cell lymphoma due to safety concerns and unsatisfactory benefit-risk data. Following this decision, the company will implement a workforce reduction of approximately 50% to conserve cash and prioritize its CRG-023 product candidate, which is on track for a Phase 1 study in Q2 2025. Despite an overall response rate of 77% in the FIRCE-1 study, the durability of response was low, and significant safety issues were identified, leading the company to conclude that firi-cel does not offer a competitive profile for patients. CARGO plans to continue its research on CRG-023 and its allogeneic platform while evaluating strategic options and expects its existing financial resources to last until mid-2028.
Potential Positives
- CARGO expects its cash runway to be extended into mid-2028, providing financial stability for ongoing research and development efforts.
- The company is continuing to advance its CRG-023 candidate into a Phase 1 dose escalation study, indicating ongoing commitment to its clinical pipeline.
- CARGO's focus on evaluating strategic options could open opportunities for partnerships or collaborations that may enhance its capabilities and reach in the market.
Potential Negatives
- Discontinuation of the FIRCE-1 Phase 2 clinical study raises concerns about the effectiveness and safety of the firi-cel treatment, highlighting potential limitations in CARGO's product pipeline.
- Reduction of the workforce by approximately 50% indicates significant financial strain and may affect the company's operational capabilities and morale.
- High incidence of serious adverse events related to the treatment raises questions about the company's ability to ensure patient safety and could impact future clinical trial recruitment.
FAQ
What is CARGO Therapeutics discontinuing?
CARGO Therapeutics is discontinuing the FIRCE-1 Phase 2 clinical study of firicabtagene autoleucel (firi-cel).
What are the reasons for discontinuing the FIRCE-1 study?
The results did not support a competitive benefit-risk profile for patients due to safety concerns and durability issues.
How will CARGO support its operations after this decision?
CARGO plans to implement a workforce reduction of approximately 50% to extend its cash runway and prioritize other projects.
What is the future direction for CARGO Therapeutics?
CARGO will continue advancing CRG-023 into Phase 1 and exploring its novel allogeneic platform while evaluating strategic options.
When is CRG-023 expected to begin its Phase 1 study?
The Phase 1 dose escalation study for CRG-023 is on track to initiate in Q2 2025.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRGX Insider Trading Activity
$CRGX insiders have traded $CRGX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $CRGX stock by insiders over the last 6 months:
- GINA CHAPMAN (President & CEO) has made 0 purchases and 2 sales selling 10,141 shares for an estimated $254,231.
- ANUP RADHAKRISHNAN (Chief Financial Officer) sold 1,600 shares for an estimated $40,452
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRGX Hedge Fund Activity
We have seen 55 institutional investors add shares of $CRGX stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,087,437 shares (+74.5%) to their portfolio in Q3 2024, for an estimated $20,063,212
- WOODLINE PARTNERS LP added 1,011,475 shares (+inf%) to their portfolio in Q3 2024, for an estimated $18,661,713
- VANGUARD GROUP INC added 600,211 shares (+41.1%) to their portfolio in Q3 2024, for an estimated $11,073,892
- COWEN AND COMPANY, LLC removed 554,305 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $10,226,927
- PRICE T ROWE ASSOCIATES INC /MD/ removed 483,765 shares (-15.2%) from their portfolio in Q3 2024, for an estimated $8,925,464
- GEODE CAPITAL MANAGEMENT, LLC added 374,018 shares (+80.6%) to their portfolio in Q3 2024, for an estimated $6,900,632
- SIO CAPITAL MANAGEMENT, LLC added 173,860 shares (+inf%) to their portfolio in Q3 2024, for an estimated $3,207,717
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)
1
; Company believes results do not support a competitive benefit-risk profile for patients.
CARGO to implement a workforce reduction of approximately 50%.
Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025.
SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) --
CARGO Therapeutics, Inc.
(Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients, today announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. In-line with this decision, the Company will reduce its workforce to extend cash runway and prioritize the advancement of CRG-023 to Phase 1 proof-of-concept data as well as its novel allogeneic platform.
Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended patient population. While data from 51 patients with at least one post baseline scan demonstrated an overall response rate of 77% and complete response rate (CR) of 43%, the durability of CR at three months was 18%. Safety data indicated 18% of patients developed immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) that were grade 3 or higher, including grade 4 and grade 5 serious adverse events. IEC-HS is a toxicity that is associated with CAR T-cell therapy and firi-cel in other clinical studies.
The Company is implementing a workforce reduction of approximately 50% to preserve cash. Further, CARGO will continue to advance CRG-023, its tri-specific CAR T, into a Phase 1 dose escalation study and its allogeneic platform to lead vector candidate selection while evaluating its strategic options. With preliminary cash, cash equivalents and marketable securities of $368.1 million
(
2
)
as of December 31, 2024, the Company expects its cash runway to be extended into mid-2028.
“We are disappointed with these unexpected results from our Phase 2 study. Durability of complete response is an important clinical goal for LBCL patients who are R/R to CD19 CAR T-cell therapy. Combined with a higher-than-expected occurrence and severity of IEC-HS, the data generated so far does not meet our expectations of a competitive benefit-risk profile for patients in the context of available treatment options. Therefore, we believe it is in the best interest of both patients and shareholders to discontinue the study,” said Gina Chapman, President and Chief Executive Officer of CARGO Therapeutics. “While we continue to advance CRG-023 into the clinic this year and progress our novel allogeneic platform, we will also evaluate our strategic options. We are grateful for the patients, caregivers and families who were involved in the FIRCE-1 study, as well as the investigators who partnered closely with us and with whom we look forward to continuing to collaborate. I’d also like to recognize and thank all of our employees at CARGO, including those being impacted by today’s decision, who have worked tirelessly on behalf of patients and made meaningful contributions to our Company’s mission.”
CARGO intends to present an analysis of the FIRCE-1 Phase 2 study at a future medical conference.
About CARGO Therapeutics
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company advancing next-generation, best-in-class, and potentially curative cell therapies for cancer patients. CARGO’s programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and availability. CARGO has a focused pipeline that includes its CRG-023 product candidate, a CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a broad range of B-cell malignancies with the goal of providing more patients with a durable complete response. CARGO’s latest program advancement, a novel allogeneic platform, is a universal vector solution designed to limit immune-based rejection and enable durable response of CAR T-cell therapy. The universal allogeneic-enabling vector is intended to be paired with any CAR vector to create an allogeneic CAR T-cell therapy, with the potential to maintain the efficacy, durability, and safety of autologous cell therapy while broadening availability to more people with cancer. CARGO’s leadership and team have significant experience in designing, developing and delivering oncology and cell therapy products. For more information, please visit the CARGO Therapeutics website at
https://cargo-tx.com/
.
Follow us on LinkedIn:
CARGO Therapeutics
Follow us on X (Twitter):
@CARGOTx
(
1
)
Firicabtagene autoleucel (firi-cel) is CARGO Therapeutics’ autologous CD22 CAR T-cell product candidate. The underlying CAR of which CARGO exclusively in-licensed from the National Cancer Institute was the construct evaluated by Stanford Medicine in a Phase 1 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. CARGO’s firi-cel Investigational New Drug application included a comprehensive package in which CARGO performed and demonstrated analytical comparability of CRG-022 produced using the intended commercial process to the CRG-022 produced using the process used for the Stanford Phase 1 clinical trials. CARGO cannot assure that the FDA will agree with its claim of comparability and the sufficiency of the data to support it when it files its Biologics License Application.
(2)
The Company’s actual consolidated cash, cash equivalents, marketable securities as of December 31, 2024 may differ from this preliminary estimate due to the completion of the Company’s year-end closing and auditing procedures.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the indication, timing, progress, advancement and results of CARGO’s clinical and preclinical programs; CARGO’s strategic plans for its business and product candidates, including its ongoing evaluation of strategic options; the Company’s expectations and estimates regarding the planned reduction in force and discontinuation of the clinical development of firi-cel; and CARGO’s estimated cash, cash equivalents and marketable securities as of December 31, 2024 and CARGO’s expectations that its current cash, cash equivalents and marketable securities will be sufficient to fund its expected operations into mid-2028. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the Company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the Company’s product candidates and the product candidates involving novel technologies; clinical and preclinical development being a lengthy and expensive process with uncertain outcomes; data from the Company’s clinical trials and preclinical studies, including the performance and characteristics of the Company’s product candidates, including any undesirable side effects or other properties discovered or detected in the Company’s clinical trials and preclinical studies; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates, if approved; the Company’s reliance on third-party suppliers and manufacturers, including CROs; the outcomes of future collaboration agreements; and the Company’s ability to adequately maintain intellectual property rights for its product candidates. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CARGO’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission, including but not limited to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed on November 12, 2024. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact:
Denise Powell
denise@redhousecomms.com
Investor Contact:
Jessica Serra
jserra@cargo-tx.com
Laurence Watts
laurence@newstreetir.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
